ArticleHematology. American Society of Hematology. Education Program2020
Monoclonal gammopathies of clinical significance.
Article in Hematology. American Society of Hematology. Education Program, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 63 citations in OpenAlex.
- Prevalence of corneal findings and their interrelation with hematological findings in monoclonal gammopathy.PloS one · 2022Trial
- Article
- Monoclonal gammopathy of clinical significance: a multisystem review.Blood cancer journal · 2026Review
- Monoclonal Gammopathy of Neurological Significance: Toward an Integrated Hematologic-Neurologic Perspective-A Single-Center Retrospective Study.International journal of molecular sciences · 2026Article
- Article
- Immune-mediated multisystem injury associated with monoclonal gammopathy of clinical significance: a case report.Frontiers in immunology · 2026Article
- [Retrospective analysis of a patient cohort with suspicion of systemic amyloidosis, finally not confirmed].Deutsche medizinische Wochenschrift (1946) · 2025Article
- Monoclonal Gammopathies of Clinical Significance-Scleromyxedema: A Case Report and Literature Review.Clinical case reports · 2025Article
- Vacuolar myopathy associated with lambda light chain myeloma: a case report and review of the literature.BMC musculoskeletal disorders · 2025Review
- Monoclonal Gammopathy of Undetermined Significance with Associated Necrotizing Myopathy: A Case Report and Review of the Literature.European journal of case reports in internal medicine · 2025Article
- Case report: Therapeutic use of bortezomib in a patient with Schnitzler syndrome.Frontiers in immunology · 2025Article
- Monoclonal gammopathy in systemic lupus erythematosus is associated with distinctive clinical course, malignancy and mortality rate: a single-centre retrospective cohort study.Lupus science & medicine · 2024Article
- Monoclonal Gammopathy of Clinical Significance (MGCS) and Related Disorders: A Review and the Role of Imaging.Diagnostics (Basel, Switzerland) · 2024Review
- Article
- Long Term Remission of Capillary Leak Syndrome Associated with Monoclonal Gammopathy with Progression to Multiple Myeloma After Autologous Stem Cell Transplantation: a Case Report and Review of the Literature.Oncology and therapy · 2024Article
- Does Systemic Hematological Therapy Influence the Course of Paraproteinemic Keratopathy?Journal of clinical medicine · 2024Article
- IgM monoclonal gammopathy of undetermined significance: clinicopathologic features with and without IgM-related disorders.Haematologica · 2023Article
- Prevalence of MGCS Among Patients With Monoclonal Gammopathies.HemaSphere · 2023Article
- Editorial: Monoclonal gammopathies of clinical significance: Clinical and therapeutic implications.Frontiers in endocrinology · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
"Monoclonal gammopathy of clinical significance" (MGCS) is the term used to describe nonmalignant monoclonal gammopathies causing important disease. MGCS is the differential diagnosis for any patient presenting with what appears to be a monoclonal gammopathy of undetermined significance but is also experiencing other unexplained symptoms. Broadly, these conditions can be separated into symptoms and signs referable to the nerves, the kidneys, and the skin. The first step in making these diagnoses is to consider them. With a particular condition in mind, the next step is to order those tests that can help confirm or dismiss a particular diagnosis. Nearly all of the renal and dermatologic conditions are diagnosed by renal and skin biopsies, respectively. The importance of a highly competent renal pathologist and dermatopathologist cannot be underestimated. Biopsy is less specific for the neuropathic conditions. Because several of the MGCSs are syndromes, recognizing other manifestations is also key. Treatment recommendations for many of these conditions are anecdotal because of their rarity, but for several of the conditions, IV immunoglobulin, rituximab, and plasma cell-directed therapy are the best options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.